Real-world use of lutetium therapy for advanced prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This study follows men with advanced prostate cancer who are receiving a new radioactive treatment called lutetium (177Lu) vipivotide tetraxetan. The goal is to see how well the treatment works in everyday practice, and to gather information on safety and effectiveness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult man with prostate cancer that has spread to other parts of the body (either castration-resistant or hormone-sensitive).
- Your doctor has decided to treat you with a medicine called lutetium (177Lu) vipivotide tetraxetan, and you are either about to start or have started within the last 2 weeks.
- Your vital organs, like your kidneys and bone marrow, must be working well enough for this treatment (your doctor will check).
- You cannot be joining any other clinical trial or another Novartis study for the same medicine at the same time.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tracks the experiences of men with metastatic prostate cancer who have received lutetium PSMA therapy (also known as Pluvicto). It aims to learn more about how this treatment works in real-world settings by collecting health information over time.
This study looks at how men with advanced prostate cancer (mCRPC) do when they receive a treatment called Pluvicto (lutetium vipivotide tetraxetan) in real-world settings. It aims to collect information on treatment effectiveness and quality of life without adding any extra procedures or medications.
This study looks at patients treated with a radioactive drug called 177Lu-PSMA-617 for a type of prostate cancer that has spread, stopped responding to hormone therapy, and has been treated with chemotherapy. It checks how the treatment affects the body and the tumor using images.
This study is observing how well the treatment lutetium-177-PSMA-617 works in people with metastatic castration-resistant prostate cancer. It aims to gather real-world information about its effectiveness and safety.
This study tracks how well a radioactive treatment (lutetium-PSMA) works for men with advanced prostate cancer that no longer responds to hormone therapy. Researchers will use imaging scans to see which patients benefit most and how quickly the treatment takes effect.
This trial tests two different dosing schedules of a drug called Lutetium-177 PSMA RLT, which delivers radiation directly to prostate cancer cells. It is for men with advanced prostate cancer that has stopped responding to hormone therapy and has spread, who have not yet had chemotherapy for this stage of the disease.
Hear when a new Metastatic Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.